[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$6163b](/topic/$6163b)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$NVO busy spending money on acquisitions. Value = unclear. Meanwhile $LLY with another great quarter. Maybe I should be investing in $LLY instead of $NVO Eli Lilly's Q3 numbers: - Revenue: $17.60B (Est. $16.07B) 🟢+54% YoY - EPS (Non-GAAP): $XXXX (Est. $5.89) 🟢 - Gross Margin: 82.9%🟢 FY25 Guidance raised -- - Revenue: $63.0B$63.5B (Est. $61.63B) 🟢 - EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) 🟢 $LLY CEO David Ricks: Lilly delivered another strong quarter with XX% revenue growth year-over-year driven by continued demand for our incretin portfolio". " We advanced Orforglipron through four"  
[X Link](https://x.com/TacticzH/status/1983854319381201002) [@TacticzH](/creator/x/TacticzH) 2025-10-30T11:11Z 29.5K followers, 28.9K engagements


"$LLY Eli Lilly Q325 Earnings Highlights 🔹 Revenue: $17.60B (Est. $16.07B) 🟢; UP +54% YoY 🔹 EPS (Non-GAAP): $XXXX (Est. $5.89) 🟢 🔹 Gross Margin: XXXX% FY25 Guidance 🔹 Revenue: $63.0B$63.5B (Est. $61.63B) 🟢 🔹 EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) 🟢 🔹 Adj. Gross Margin: XX% 🔹 Performance Margin: 45%46% (Non-GAAP) Segment 🔹 Mounjaro: $6.52B; UP +109% YoY 🔹 Zepbound: $3.59B; UP +185% YoY 🔹 Verzenio: $1.47B; UP +7% YoY Other Metrics 🔹 U.S. Revenue: $11.30B; UP +45% YoY 🔹 OUS Revenue: $6.30B; UP +74% YoY CEO Commentary 🔸 Lilly delivered another strong quarter with XX% revenue"  
[X Link](https://x.com/wallstengine/status/1983848335736746296) [@wallstengine](/creator/x/wallstengine) 2025-10-30T10:47Z 101.7K followers, 45K engagements